Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The taxanes: dosing and scheduling considerations

¹Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, USA.

Oncology (Williston Park, N.Y.)

|March 1, 1997

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.

British journal of cancer·2011

Same author

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.

British journal of cancer·2011

Same author

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2010

Same author

Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2007

Same author

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2005

Same author

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

Annals of oncology : official journal of the European Society for Medical Oncology·2004

Optimal taxane dosing and scheduling are crucial for maximizing antitumor efficacy. Doses and schedules must be carefully considered, as effectiveness plateaus above a certain threshold, which is inversely related to administration duration.

Area of Science:

Oncology
Pharmacology
Clinical Trials

Background:

Optimal dosing and scheduling of taxanes are critical in clinical research.
Current studies suggest no single administration schedule guarantees maximum antitumor efficacy.

Purpose of the Study:

To analyze the relationship between taxane dosing, scheduling, and antitumor efficacy.
To determine how dose-response curves are affected by administration schedule duration.

Main Methods:

Review of clinical studies on taxane dosing and scheduling.
Analysis of dose-response relationships for paclitaxel and docetaxel.
Examination of threshold and plateau effects in taxane therapy.

Main Results:

Related Experiment Videos

Taxane efficacy depends on specific doses relative to schedule and overall aggressiveness.

Threshold and plateau doses are inversely proportional to administration schedule duration.

Paclitaxel shows comparable efficacy with short (1-3h) and prolonged (24-96h) schedules at equitoxic doses.

Docetaxel studies suggest a dose-response relationship between 60-100 mg/m2, with 100 mg/m2 over 1 hour at the upper dosing limit.

Conclusions:

Taxane efficacy is influenced by a complex interplay of dose and schedule.
Administration schedule duration significantly impacts dose-response thresholds and plateaus.
Tailoring taxane dosing and scheduling is essential for optimizing patient outcomes.